Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

N Engl J Med. 2021 Sep 30;385(14):1302-1315. doi: 10.1056/NEJMra1907607.

Authors

Daniel C Baumgart¹, Catherine Le Berre¹

Affiliation

¹ From the Division of Gastroenterology, University of Alberta, Edmonton, Canada (D.C.B.); and Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, and the Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy - both in France (C.L.B.).

PMID: 34587387
DOI: 10.1056/NEJMra1907607

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Biological Products / therapeutic use*
Diet Therapy
Drug Therapy, Combination
Humans
Indans / therapeutic use
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / physiopathology
Inflammatory Bowel Diseases / therapy
Interleukins / antagonists & inhibitors
Oxadiazoles / therapeutic use
Piperidines / therapeutic use
Pyrimidines / therapeutic use
Remission Induction
Stem Cell Transplantation
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

Antibodies, Monoclonal
Biological Products
Indans
Interleukins
Oxadiazoles
Piperidines
Pyrimidines
Tumor Necrosis Factor Inhibitors
tofacitinib
ozanimod